Optics11 Life, an Amsterdam-based company known for its mechanobiology tools, has announced a new funding round aimed at broadening its financial and operational capabilities. The firm is aligning with the growing demand for advanced life sciences instrumentation by pushing the frontiers of drug development and regenerative medicine. A surge in investments highlights confidence in the company’s potential to further influence biotech and pharmaceutical sectors globally.
In previous years, Optics11 Life concentrated on optimizing its mechanobiology instruments to assist in drug development and reducing animal testing. The focus on expanding global operations is a recent shift that mirrors the funding rounds that have increasingly backed ventures with sustainable and efficient approaches in these fields. By receiving support from established firms like Forward.one and ECFG, Optics11 Life gains both financial support and strategic expertise.
What Will the New Capital Fund?
The newly acquired funds will bolster Optics11 Life’s endeavors in enhancing its mechanobiology instruments designed to evaluate cell and tissue mechanics. The company aims to lower dependence on animal testing while enhancing drug development processes. This funding will be directed towards expanding commercial operations in major markets such as the US, Europe, and Asia, thereby making products more accessible.
“We are thrilled to welcome ECFG to our investor group and to continue our strong collaboration with Forward.one and VCC,”
stated CEO Hans Brouwer.
How Does Optics11 Life Advance Research?
Optics11 Life, established in 2011, develops cutting-edge instruments that evaluate the mechanical properties of cells, tissues, and biomaterials. Using fibre-optic sensing technology, the firm facilitates high-throughput mechanical screening which is essential for fields like drug development and regenerative medicine. The tools like Pavone, Piuma, Chiaro, and Cuore serve various scientific needs ranging from nanoindentation to monitoring muscle-bundle dynamics.
“This investment enables us to accelerate our mission to provide researchers and biotech companies with solutions they need,”
Brouwer added.
The expansion is expected to facilitate collaborations with researchers focusing on New Approach Methodologies (NAMs), delivering more effective treatments devoid of animal testing. By empowering researchers, Optics11 Life fosters advancements in personalized medicine and regenerative therapies.
With a team of over 60 employees, the company is driven by the mission to create impactful solutions without the ethical concerns linked to animal testing. It’s part of their broader vision to make vital treatments more accessible and affordable, echoing a commitment to transformative research methodologies.
Optics11 Life’s strategic moves reflect an understanding of industry trends, demonstrating their capability to drive meaningful advances in mechanobiology. Enhanced funding not only supports their technological development but also cements their standing as a pivotal player in the global life sciences industry. By prioritizing sustainable practices and innovative tools, Optics11 Life ensures a future-ready approach that addresses both scientific and ethical considerations.
